Medicine
Sickle Cell Disease news, research, studies, and rapid health briefings. Visit Viral Vitalism for plain-language context, evidence boundaries, and related signals.
News cycle
A young actress and Spelman graduate is preparing for Casgevy after years of sickle-cell pain crises, but her treatment story is still pre-infusion.
Why now
McKenzie's story lets VV track a Casgevy journey from collection and manufacturing through infusion, rather than only covering the post-treatment headline.
Two NEJM-published experimental approaches show the sickle-cell gene therapy field moving from one breakthrough toward multiple strategies.
Why now
Columbia's update helps shift the sickle-cell gene therapy narrative from a single approved breakthrough to an emerging field of distinct strategies, risks, and access tradeoffs.
Sickle cell disease blocked Daniel Cressy's path to becoming a commercial pilot. New national coverage sharpened the human angle: he calls the post-Casgevy chapter his second life.
Why now
A patient-level milestone is moving gene therapy from approval news into real-world care in Louisiana and national coverage.
Vital Signals
Get the weekly health signal without the wellness fog.
A clean weekly brief covering longevity science, fitness, nutrition, medicine, health culture, and the claims worth questioning.
No spam. No miracle claims. Just better health signal.
By subscribing, you agree to receive email from Viral Vitalism. Unsubscribe anytime. See our Privacy Policy.
